High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer

Tan, Iain Beehuat; Malik, Simeen; Ramnarayanan, Kalpana; McPherson, John R; Ho, Dan Liang; Suzuki, Yuka; Ng, Sarah Boonhsui; Yan, Su; Lim, Kiat Hon; Koh, Dennis; Hoe, Chew Min; Chan, Chung Yip; Ten, Rachel; Goh, Brian KP; Chung, Alexander YF; Tan, Joanna; Chan, Cheryl Xueli; Tay, Su Ting; Alexander, Lezhava; Nagarajan, Niranjan; Hillmer, Axel M; Tang, Choon Leong; Chua, Clarinda; Teh, Bin Tean; Rozen, Steve; Tan, Patrick

doi:10.1186/s13059-015-0589-1

Table 1 Patient characteristics

From: High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer

No.	Temporal relationship of metastasis to primary tumor	MSI status	KRAS/BRAF mutational status	Stage at diagnosis	Month of surgery for primary tumor	Adjuvant therapy	Disease-free interval	Date of diagnosis of recurrence	Chemotherapy for metastasis	Objective response to chemotherapy	Month of liver resection
1	Synchronous	MSS	Wild type for both	4	Jun 2012				3 cycles of XELOX	Partial response	Nov 2012
2	Synchronous	MSS	Wild type for both	4	Oct 2012						Oct 2012
3	Synchronous	MSS	Wild type for both	4	Jan 2011						Jan 2011
4	Synchronous	MSS	Wild type for both	4	May 2011				5 cycles of XELOX	Partial response	Oct 2011
5	Metachronous	MSS	Wild type for both	3	Nov 2010	XELOX	22 months	Aug 2012			Aug 2012
6	Synchronous	MSS	Wild type for both	4	Nov 2012						Nov 2012
7	Metachronous	MSS	Wild type for both	3	Nov 2011	Xeloda/RT and XELOX	8 months	Jul 2012	3 cycles of XELIRI	Stable disease	Nov 2012
8	Synchronous	MSS	Wild type for both	4	Jul 2013						Jul 2013
9	Synchronous	MSS	Wild type for KRAS	4	Jul 2011				6 cycles of XELOX and cetuximab	Stable disease	Jan 2012
10	Synchronous	MSS	Wild type for both	4	Apr 2013				8 cycles of XELOX	Stable disease	Apr 2014
11	Synchronous	MSS	Wild type for both	4	Mar 2014				6 cycles of FOLFOX with cetuximab from cycle 3 onwards	Stable disease	Apr 2014
12	Synchronous	MSS	Wild type for both	4	Aug 2013						Dec 2013
13	Metachronous	MSS	Wild type for both	2	Jun 2012	None	19 months	Jan 2014			Feb 2014
14	Synchronous	MSS	KRAS p.G12V	4	May 2014						May 2014
15	Synchronous	MSS	KRAS p.G12V	4	May 2014				8 cycles of XELOX	Partial response	May 2014
16	Metachronous	MLH-1 and PMS-2 loss	Wild type for KRAS	2	Aug 2004	None	78 months	Feb 2011			May 2012
17	Synchronous	MSS	Wild type for both	4	Mar 2012				2 cycles of XELOX and cetuximab	Partial response	May 2012
18	Synchronous	MSS	Wild type for both	4	Mar 2013						Mar 2013

Clinico-pathologic and treatment details for the 18 patients. MSI: microsattelite instability; MSS: microsattelite stable.

Back to article page

ISSN: 1474-760X

Contact us

Submission enquiries: editorial@genomebiology.com
General enquiries: info@biomedcentral.com

Genome Biology

Contact us